logo
  

Takeda: TAK-003 Shows 84.1% Vaccine Efficacy Against Hospitalized Dengue In Long-term TIDES Trial

Takeda (TAK) said its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years after vaccination in the phase 3 Tetravalent Immunization against Dengue Efficacy Study trial. The company said these long-term results supplement previously published TIDES data that showed the candidate vaccine met its primary endpoint of overall vaccine efficacy against virologically-confirmed dengue.

The company noted that, while the long-term follow-up for the primary two-dose series has been completed, the TIDES trial remains ongoing to evaluate the safety and efficacy of a booster dose.

TAK-003 is undergoing regulatory review for the prevention of dengue disease in children and adults in the European Union and select dengue-endemic countries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Activity in the U.S. manufacturing sector slowed by more than expected in the month of September but still saw continued growth, according to a report released by the Institute for Supply Management on Monday. Stocks have moved sharply higher in morning trading on Monday, regaining ground following a dismal September. The major averages have all shown substantial moves to the upside. Swedish geneticist Svante Paabo has won this year's Nobel Prize in Physiology/Medicine for his discoveries concerning the genomes of extinct hominins and human evolution. Through his pioneering research, Svante Pääbo accomplished something seemingly impossible: sequencing the genome of the Neanderthal, an extinct relative of present-day humans. He also made the sensational discovery of a previous
Follow RTT